A MICROFLUIDIC AND MACHINE LEARNING-ENABLED SMARTLAB FOR AUTONOMOUS REMOTE EXECUTION AND ITERATION OF MULTISCALE LIVE CELL ASSAYS FOR DRUG DISCOVERY

支持微流控和机器学习的智能实验室，用于自主远程执行和迭代多尺度活细胞测定以进行药物发现

• 批准号: 10505107
• 负责人: MARY LUDLAM
• 金额: $ 33.15万
• 依托单位: CAIRN BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2022-06-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10505107
• 关键词: Address; Artificial Intelligence; Biological Assay; Cells; Cellular Assay; Data Analyses; Data Storage and Retrieval; Development; Drug usage; Feedback; Goals; Health; Human; Infrastructure; Interruption; Machine Learning; Microfluidics; Monitor; Persons; Reagent; Risk; Scientist; Secure; Time; assay development; base; cloud based; cost; drug discovery; experimental study; human error; improved; innovation; instrumentation; operation; pre-clinical; prototype; remote control; wasting

Preclinical drug discovery assay development depends on the presence of scientists to develop, initiate and monitor assays. Interruptions and errors in the execution of these activities incur extra time and expense to restart experiments and the waste of previously expended time and reagents. The innovative SmartLab framework envisioned by this project addresses the significant, costly risks of interruptions and errors in preclinical cell-based assays by enabling their remote, autonomous initiation, execution and iteration. Advantages of the SmartLab framework include (1) reduction in risk of human error; (2) unimpeded continuation of experiments when in-person lab operations are interrupted and (3) maximized experimental efficiency through adaptive experimental feedback. Collectively these advantages will benefit human health by dramatically improving the robustness and efficiency of preclinical assay frameworks used for drug discovery.

临床前药物发现测定的开发取决于科学家的存在，启动和监测分析。这些活动的执行中的中断和错误会产生额外的时间和费用，以重新启动实验以及浪费先前花费的时间和试剂。该项目设想的创新的SmartLab框架通过启用其远程，自主的启动，执行和迭代，解决了基于临床前单元格测定法中中断和错误的巨大风险和错误的风险。 SmartLab框架的优点包括（1）降低人为错误的风险； （2）当面对面实验室操作中断时，实验的持续不受阻碍，（3）通过自适应实验反馈最大化实验效率。这些优势总的来说，将通过显着提高用于药物发现的临床前分析框架的鲁棒性和效率来使人类健康受益。